Full Press Release Details
Rhythm Pharmaceuticals Launches IMCIVREE setmelanotide in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency.
RYTM
Rhythm Pharmaceuticals Launches IMCIVREE setmelanotide in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency
Key Takeaway: Rhythm Pharmaceuticals Launches IMCIVREE setmelanotide in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency